Psyence EBITDA from 2010 to 2024

PBM Stock  USD 3.51  0.17  5.09%   
Psyence Biomedical EBITDA yearly trend continues to be very stable with very little volatility. EBITDA is likely to grow to about -2.6 M this year. During the period from 2010 to 2024, Psyence Biomedical EBITDA quarterly data regression pattern had range of 2.4 M and standard deviation of  837,862. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-2.8 M
Current Value
-2.6 M
Quarterly Volatility
837.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Psyence Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Psyence Biomedical's main balance sheet or income statement drivers, such as Interest Income of 1.4 K, Selling General Administrative of 1.8 M or Selling And Marketing Expenses of 84.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Psyence financial statements analysis is a perfect complement when working with Psyence Biomedical Valuation or Volatility modules.
  
Check out the analysis of Psyence Biomedical Correlation against competitors.

Latest Psyence Biomedical's EBITDA Growth Pattern

Below is the plot of the Ebitda of Psyence Biomedical Ltd over the last few years. It is Psyence Biomedical's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Psyence Biomedical's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (2.75 M)10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Psyence EBITDA Regression Statistics

Arithmetic Mean(711,403)
Coefficient Of Variation(117.78)
Mean Deviation603,380
Median(334,290)
Standard Deviation837,862
Sample Variance702B
Range2.4M
R-Value(0.67)
Mean Square Error414.5B
R-Squared0.45
Significance0.01
Slope(125,929)
Total Sum of Squares9.8T

Psyence EBITDA History

2024-2.6 M
2023-2.8 M
2022-1.3 M

About Psyence Biomedical Financial Statements

Psyence Biomedical investors utilize fundamental indicators, such as EBITDA, to predict how Psyence Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-2.8 M-2.6 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Psyence Biomedical is a strong investment it is important to analyze Psyence Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Psyence Biomedical's future performance. For an informed investment choice regarding Psyence Stock, refer to the following important reports:
Check out the analysis of Psyence Biomedical Correlation against competitors.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psyence Biomedical. If investors know Psyence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psyence Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.82)
Return On Assets
(1.26)
The market value of Psyence Biomedical is measured differently than its book value, which is the value of Psyence that is recorded on the company's balance sheet. Investors also form their own opinion of Psyence Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Psyence Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psyence Biomedical's market value can be influenced by many factors that don't directly affect Psyence Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psyence Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Psyence Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psyence Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.